Genetic engineering concept. Medical science. Scientific Laboratory.
image-

Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Posted on

STONY BROOK, N.Y. – June 29, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced the formal launch of business development initiatives to expand the biotherapeutics industry’s awareness of the LinearDNA™ platform (the “platform”) as an alternative to current plasmid-based (pDNA) production processes used in the […]

Read More email

image-

Beefing Up Cancer Treatments, With A Vaccine In Sight

Posted on

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

Read More email

image-

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

Posted on

Four days before the first cases of COVID-19 were confirmed in Italy on January 31, a small biotech firm in the outskirts of Rome announced it was pivoting its business. Researchers at Takis Biotech, which had been focused on cancer treatments, would instead set about developing a vaccine for the rapidly spreading coronavirus. With the virus […]

Read More email

image-

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

Posted on

[vc_single_image image=”19473″ img_size=”large”] Cure bet: If vaccine candidates prepared by Applied DNA’s LinearDNA manufacturing system perform as well as plasmid-based candidates prepared by Italian biopharma Takis Biopharma, the cross-Atlantic collaboration may be on to something. APRIL 15, 2020 By GREGORY ZELLER // With preliminary lab tests looking good, an innovative Long Island biotech is rushing […]

Read More email

image-

Stony Brook firm working on coronavirus vaccine

Posted on

A Stony Brook anti-counterfeiting company is seeking to adapt its DNA expertise to create a coronavirus vaccine with an Italian biotechnology partner. Applied DNA Sciences Inc. on Monday announced that it is expanding its alliance with Rome-based Takis Biotech on four potential vaccines to test on animals. In February, the companies announced a joint development […]

Read More email

image-

Pharmaceutical Technology | Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

Posted on

[vc_single_image image=”19103″ img_size=”large” el_class=”graphic”] The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences and Takis Biotech have designed four Covid-19 vaccine candidates to help protect against the novel coronavirus. The companies plan to manufacture the DNA vaccine candidates using PCR-based DNA (LinearDNA) manufacturing systems for preclinical testing in animals. Last month, Applied […]

Read More email

image-

Applied DNA Speeds Coronavirus Vaccines Toward Tests

Posted on

MARCH 2, 2020 By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the Stony Brook-based biotech’s unique DNA-manufacturing abilities, Rome, Italy-based Takis Biotech will test potential vaccines against the coronavirus (now going by COVID-19) in laboratory mice, on a large scale. Applied […]

Read More email

image-

Applied DNA To Speed Up Coronavirus Countermeasures

Posted on

By GREGORY ZELLERLook out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will […]

Read More email

image-

Applied DNA, Takis Biotech partner on coronavirus vaccine

Posted on

[vc_single_image image=”19103″ img_size=”large” el_class=”graphic”] The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus. LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on […]

Read More email

image-

LineaRx signs agreement with TYME Technologies

Posted on

Applied DNA Sciences announced that LineaRx, the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services for use in the pivotal stage of the TYME-88-PANC clinical trial for patients with third-line pancreatic […]

Read More email

image-

‘Linear DNA’ Combo Shows Punch In Cancer Fight

Posted on

[vc_single_image image=”17928″ img_size=”large”] By GREGORY ZELLER //SEPTEMBER 19, 2019 Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of […]

Read More email

image-

For Applied DNA, New Blood — And A Shot In The Arm

Posted on

AUGUST 12, 2019 By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition. LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony […]

Read More email

image-

LineaRx Acquires Cancer Cell Analysis Firm Vitatex

Posted on

August 8, 2019 NEW YORK — LineaRx said today that it has acquired the assets and intellectual property of Vitatex, a developer of invasive circulating tumor cell (iCTC) analysis technologies. According to LineaRx — an Applied DNA Sciences subsidiary formed around technologies for DNA design, manufacture, and chemical modification by large scale PCR —  Vitatex’s technologies allows […]

Read More email

image-

Linear DNA Crosses the Line between Tags and Therapeutics

Posted on

Short fragments of linear DNA are used for molecular tagging in a variety of industries, from textiles to pharmaceuticals, to provide product authentication and ingredient traceability. Applied DNA Sciences is now translating its expertise in the molecular tagging industry to the biopharma industry. Its subsidiary, LineaRx, is manufacturing large, gene-sized fragments of linear DNA for […]

Read More email

image-

At LineaRX, Putting The Horsepower Behind The CAR T

Posted on

[vc_single_image image=”15087″ img_size=”large”] Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies. By GREGORY ZELLER //OCTOBER 16, 2018 Marking a big step in the war against cancer, a Stony Brook-based startup […]

Read More email

image-

Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals

Posted on

[vc_single_image image=”14679″ img_size=”full”] Streamlined manufacturing processes could yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. [Applied DNA Sciences] By MaryAnn Labant A rapidly emerging immunotherapy approach, adoptive cell transfer (ACT), collects and uses a patient’s own immune cells to treat their cancer. One methodology, Chimeric Antigen Receptor T-Cell (CAR T-cell) […]

Read More email

image-

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

Posted on

Published: Sep 20, 2018 By Mark TerryLineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will use […]

Read More email

image-

With New Spinoff, Biotech Goes All-In On DNA Sales

Posted on

[vc_single_image image=”16463″ img_size=”large”]Chain reaction: With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx.

Read More email